Sep 7, 2026, 15:35
Abdulaziz Hamoudi: The Multicenter Randomized PROTECT-EST Trial Reports Impressive Results for SAP
Abdulaziz Hamoudi, Business Development Manager at ENDOHUB group, shared a post on LinkedIn:
”Peptide-first for post-sphincterotomy bleeding?
The multicenter randomized PROTECT-EST trial reports impressive results for self-assembling peptide (SAP) in persistent post-sphincterotomy oozing:
- 92.3 percent immediate hemostasis vs 76.9 percent with balloon tamponade
- 7.7 percent required rescue therapy vs 23.1 percent
Promising evidence supporting a peptide-first strategy in therapeutic endoscopy.
Proud to support the advancement of PuraStat self-assembling peptide technology in our region.
Study.”
Stay updated with Hemostasis Today.
-
Sep 7, 2026, 18:36Richard Kollen: Preventing Deep Vein Thrombosis During Long Flights
-
Sep 7, 2026, 18:34Mahmoud Hashem: Apixaban – Doses According to the Reason for Use
-
Sep 7, 2026, 14:44Abdel Gaffar Mohammed: Treatment Approaches for Different Types of TMA
-
Sep 7, 2026, 18:31Julian P. Villacastin: LAAC as a Treatment Option When Long-Term Anticoagulation Is Problematic
-
Sep 7, 2026, 18:29Geoff Stooke: How Hemophilia Led the Massie Family to the Romanovs and Ronald Reagan
-
Sep 7, 2026, 18:27Sam Mbunya: September is Sickle Cell Awareness Month
-
Sep 7, 2026, 18:25David Akande: Things I Wish People Knew About Sickle Cell
-
Sep 7, 2026, 18:24Prachi Bansal: A Small Act of Giving, A Lifelong Lesson in Humanity
-
Sep 7, 2026, 17:27Isaac Okello: From Global Dialogue to Local Impact in Sickle Cell Disease